On 16.12.2024 NEOPHARM BULGARIA Ltd. launched the implementation of a project proposal entitled “Implementation in Production of an Innovative Product for the Prevention and Treatment of Constipation”, co-financed under the “Competitiveness and Innovation in Enterprises” Programme 2021-2027, procedure BG16RFPR001-1.003 “Implementation of Innovations in Enterprises”.
Financing Agreement Number: BG16RFPR001-1.003-0224-C01
Contract Duration: 15 months (until 16.03.2026)
Project Value: 1,777,777 BGN
Grant Funding: 799,999.65 BGN
Neopharm has been recognized as one of the fastest-growing companies on the pharmaceutical market in terms of speed of product launches and annual sales revenue growth. We continuously invest in new developments and equipment. With this project, our goal is to implement into regular production innovative probiotic products addressing the specific condition of constipation, based on our proprietary cultivated and isolated strain Lactiplantibacillus plantarum DSM 34434. This will allow us to close the production cycle by exercising full control over the manufacturing process. This is a key milestone in our development, as it enables us to create new products to be added to our portfolio at a faster pace, with greater effectiveness and higher quality. The project will also result in the establishment of a new production facility in Plovdiv, where the new equipment will be installed, and the probiotic product will be manufactured up to probiotic powder form.
The overall objective of the project proposal is the introduction into regular production of an innovative product – an in-house development – a product innovation targeting the specific health condition of constipation. Our competitiveness will be strengthened, opportunities for growth will be secured, and we will be able to meet the expectations of our customers and partners both in the national and international markets to a greater extent, by developing higher-quality and more effective products with complete control over all stages of the production process, achieved through closing the production cycle from strain cultivation and isolation to the final market-ready product.
Specific objectives of the project include:
1. Cultivation and industrial-scale production of the proprietary probiotic strain Lactiplantibacillus plantarum DSM 34434
2. Reducing reliance on imported probiotic strains in favor of in-house production under fully controlled conditions
3. Production of combined probiotic products with innovative formulations, protected by a patent application – a national patent application has been filed
4. Creating opportunities for the development of additional types of high value-added products
5. Establishment of a new production facility dedicated to the manufacturing of probiotic strains and probiotic-containing products
6. Introduction to the market of a new type of probiotic products providing comprehensive, rapid, and sustainable relief of the specific condition “constipation”, affecting a significant proportion of the population.
The general and specific objectives of the project are aligned with the Company’s development strategy as well as with the overall goal of the procedure, namely: “Providing targeted support to Bulgarian enterprises for the implementation of product innovations or business process innovations in the thematic areas of the Innovation Strategy for Smart Specialization 2021-2027 (IS3 2021-2027)”, since our innovation is product-based – new health-related products developed in-house, falling within the thematic area of IS3 2021-2027: Healthy Living Industry, Bioeconomy and Biotechnology. Sub-area: “Personalized Medicine, Diagnostics and Individual Therapy, Therapeutic and Pharmaceutical Forms and Tools.”
The project investments comply with the “do no significant harm” principle to the environment, ensuring that neither the acquired equipment nor the production and use of the specific products will cause any environmental damage.
The efficiency of our overall production process will be enhanced by closing the production cycle for probiotic products, ensuring control at all stages of the process. The implementation of innovative products into regular production is crucial for our future development, providing significant opportunities for portfolio expansion and increased sales revenues.
This publication has been prepared under contract BG16RFPR001-1.003-0224-C01 “Implementation in Production of an Innovative Product for the Prevention and Treatment of Constipation”, co-financed under the “Competitiveness and Innovation in Enterprises” Programme 2021-2027, procedure “Implementation of Innovations in Enterprises”.
The sole responsibility for the content of this document lies with NEOPHARM BULGARIA Ltd.